Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed by a tissue or cell sample test.
• People whose pancreatic cancer has been determined to be locally advanced and cannot be removed by surgery, based on specific reasons such as the tumor being too close to or wrapped around major blood vessels or the aorta, or surgery being considered too risky for that person.
• People whose case has been reviewed by a team of specialists, including a pancreatic surgeon, who have confirmed the cancer cannot be surgically removed.
• People who have either already received initial chemotherapy before radiation treatment, or who have been assessed by an oncologist as not being suitable for that initial chemotherapy — and where chemotherapy was received, the last dose must have been given at least 2 weeks before the radiation treatment begins (for those in the dose escalation part of the trial).
• People who are reasonably well and able to carry out daily activities, as measured by a standard scale (ECOG performance score of 0, 1, or 2).
• People whose blood counts, liver function, and kidney function meet the required levels as tested by blood tests (confirm specific values with the trial site).
• Women who could become pregnant must have a negative pregnancy test within 72 hours before joining the trial, and both men and women who could have children must agree to use effective contraception during the trial and for at least 6 months after treatment ends.
• People aged 18 years or older.
• People who are willing and able to sign consent forms, provide tissue samples, attend follow-up appointments, and comply with the treatment schedule.

Who may not be able to join:

• People whose cancer has spread to other parts of the body (metastatic disease), confirmed by imaging or cell testing.
• People who have previously received radiation therapy for pancreatic cancer.
• People who have previously received a combination of chemotherapy and radiation therapy that overlapped with the area that would be treated in this trial.
• People diagnosed with adenosquamous carcinoma of the pancreas (a different subtype of pancreatic cancer).
• People who have received chemotherapy within 2 weeks before joining the trial, or who are still experiencing significant side effects from earlier chemotherapy. People who received certain types of immunotherapy or antibody treatments within 28 days before joining, or who still have unresolved significant side effects from those treatments (confirm details with the trial site).
• People who are currently receiving other chemotherapy or biological treatments at the same time as this trial.
• People with a medical history of a condition called ataxia telangiectasia, or any other documented condition that causes unusual sensitivity to radiation. This also includes people with certain specific genetic mutations in the ATM gene that are considered likely harmful (confirm specific mutation details with the trial site).
• People who currently have a serious active infection that requires intravenous (IV) antibiotics.

Important: Always verify eligibility with the trial site directly before applying.